A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment.

Trial Profile

A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Faldaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms STARTVerso-3
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 19 May 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
    • 02 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
    • 26 Nov 2013 Faldaprevir has been granted accelerated assessment from the EMA; the MAA submission was based on a comprehensive clinical development programme with a particular focus on the phase III STARTVerso data.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top